; This proposal is a continuation of Project 2 in the original SPORE grant. Pertinent to this proposal, we have developed an anti-DRS monoclonal antibody therapy for pancreatic cancer through in vitro studies, animal model efficacy and with an industry partner (Daiichi Sankyo), Phase I and recently completed Phase II trials in pancreatic cancer. We have also discovered a novel molecule (DDX3) which appears to play a major role in regulation of anti-DRS mediated apoptosis. In this proposal, we will explore two strategies to enhance the efficacy of anti-DRS monoclonal therapy especially in pancreatic tumor cell lines which are intermediate or resistant to anti-DRS. The two strategies are to evaluate the addition of a monoclonal anti-DR4 reagent or the addition of small molecule modulators ofthe apoptosis cascade. The two apoptosis modulators to be evaluated are AT-101, a Bcl-2 family inhibitor, and AT-406, an lAP family inhibitor. These two strategies will be studied using in vitro analysis and orthotopic and metastatic xenogeneic pancreatic cancer models leading to a Phase I trial of the best strategy. In addition, we will continue studies of DDX3 and the DRS/DDX3 complex as a putative biomarker for tumor cell sensitivity/resistance to death receptor mediated anti-tumor efficacy and as the target of enhancement strategies for anti-DR mediated anti-tumor effects.

National Institute of Health (NIH)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Ramesh, Jayapal; Kim, Hwasoon; Reddy, Kartika et al. (2014) Impact of pancreatic stent caliber on post-endoscopic retrograde cholangiopancreatogram pancreatitis rates in patients with confirmed sphincter of Oddi dysfunction. J Gastroenterol Hepatol 29:1563-7
Kaliberov, S A; Kaliberova, L N; Buchsbaum, D J et al. (2014) Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Ther 21:264-74
Bohrer, Laura R; Chuntova, Pavlina; Bade, Lindsey K et al. (2014) Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res 74:374-86
Dmitriev, Igor P; Kashentseva, Elena A; Kim, Kenneth H et al. (2014) Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene. Mol Imaging 13:
Chio, Iok In Christine; Yordanov, Georgi; Tuveson, David (2014) MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J Natl Cancer Inst 106:
Auer, H; Mobley, J A; Ayers, L W et al. (2014) The effects of frozen tissue storage conditions on the integrity of RNA and protein. Biotech Histochem 89:518-28
Hébert-Magee, Shantel; Varadarajulu, Shyam; Frost, Andra R et al. (2014) Primary pancreatic leiomyosarcoma: a rare diagnosis obtained by EUS-FNA cytology. Gastrointest Endosc 80:361-2
Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94
Reddy, Kartika; Hooper, Kari; Frost, Andra et al. (2014) Intraductal papillary carcinoma of common bile duct diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 46 Suppl 1 UCTN:E248-9
Desai, Leena P; Zhou, Yong; Estrada, Aida V et al. (2014) Negative regulation of NADPH oxidase 4 by hydrogen peroxide-inducible clone 5 (Hic-5) protein. J Biol Chem 289:18270-8

Showing the most recent 10 out of 53 publications